Norucholic acid, with or without UDCA, prevents PSC progression
01 Jul 2026
bởiElaine Soliven
Patients with primary sclerosing cholangitis (PSC) who received norucholic acid (NCA), with or without ursodeoxycholic acid (UDCA) background therapy, were more likely to achieve histological and biochemical improvements than those receiving placebo, according to the subgroup analysis of the NUC-5 trial presented at EASL 2026.
Norucholic acid, with or without UDCA, prevents PSC progression
01 Jul 2026